Abstract

Primary infection with varicella zoster virus (VZV) results in varicella (more commonly known as chickenpox) after which VZV establishes latency in sensory ganglia. VZV can reactivate to cause herpes zoster (shingles), a debilitating disease that affects one million individuals in the US alone annually. Current vaccines against varicella (Varivax) and herpes zoster (Zostavax) are not 100% efficacious. Specifically, studies have shown that 1 dose of varivax can lead to breakthrough varicella, albeit rarely, in children and a 2-dose regimen is now recommended. Similarly, although Zostavax results in a 50% reduction in HZ cases, a significant number of recipients remain at risk. To design more efficacious vaccines, we need a better understanding of the immune response to VZV. Clinical observations suggest that T cell immunity plays a more critical role in the protection against VZV primary infection and reactivation. However, no studies to date have directly tested this hypothesis due to the scarcity of animal models that recapitulate the immune response to VZV. We have recently shown that SVV infection of rhesus macaques models the hallmarks of primary VZV infection in children. In this study, we used this model to experimentally determine the role of CD4, CD8 and B cell responses in the resolution of primary SVV infection in unvaccinated animals. Data presented in this manuscript show that while CD20 depletion leads to a significant delay and decrease in the antibody response to SVV, loss of B cells does not alter the severity of varicella or the kinetics/magnitude of the T cell response. Loss of CD8 T cells resulted in slightly higher viral loads and prolonged viremia. In contrast, CD4 depletion led to higher viral loads, prolonged viremia and disseminated varicella. CD4 depleted animals also had delayed and reduced antibody and CD8 T cell responses. These results are similar to clinical observations that children with agammaglobulinemia have uncomplicated varicella whereas children with T cell deficiencies are at increased risk of progressive varicella with significant complications. Moreover, our studies indicate that CD4 T cell responses to SVV play a more critical role than antibody or CD8 T cell responses in the control of primary SVV infection and suggest that one potential mechanism for enhancing the efficacy of VZV vaccines is by eliciting robust CD4 T cell responses.

Highlights

  • Varicella zoster virus (VZV), a neurotropic alphaherpesvirus, is the causative agent of varicella

  • We must identify the components of the immune system that are important for the control of VZV replication

  • Using the infection of young rhesus macaques (RM) with Simian varicella virus (SVV) as a model of acute VZV infection, we aimed to determine the role of T cell versus B cell responses during acute SVV infection

Read more

Summary

Introduction

Varicella zoster virus (VZV), a neurotropic alphaherpesvirus, is the causative agent of varicella (chickenpox). Given that by 2020 17% of the US population is estimated to be 65 years of age or older (US Census), the incidence of HZ and its associated morbidities is likely to increase. There are currently two FDA approved VZV vaccines available that contain the live attenuated VZV Oka strain: Varivax, directed against chickenpox, and Zostavax, directed against shingles. The introduction of Varivax, and of the 2-dose regimen, has dramatically reduced the incidence of chickenpox and annual varicella-related hospitalizations and deaths in the US [7,8]. Vaccination with Zostavax reduced the incidence of shingles by 51% in a 3-year study period and resulted in a 61% decrease in the burden of disease [9,10]. Recent studies showed that the cellular and humoral responses engendered by Zostavax signifi-

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call